Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/Safety of DWJ1568 vs DWC202215 in Healthy Volunteers
NCT06119945Phase 1Recruiting
- Sponsor
- Daewoong Pharmaceutical
- Start
- Nov 2023
- Primary completion
- Dec 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of DWJ1568 in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Daewoong Pharmaceutical. Primary endpoints: Maximum Plasma Concentration at Steady State and Area Under the Curve to the Last Measurable Concentration. Started Nov 2023; status: recruiting.
02
Drugs
DWJ1568
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NCT06119945.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06119945.